Colleen Kusy
Stock Analyst at Baird
(0.79)
# 3,621
Out of 4,818 analysts
42
Total ratings
23.68%
Success rate
-18.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $17.89 | +129.18% | 4 | Mar 13, 2025 | |
| AGEN Agenus | Maintains: Neutral | $6 → $3 | $2.85 | +5.26% | 2 | Mar 12, 2025 | |
| CHRS Coherus BioSciences | Maintains: Outperform | $4 → $6 | $1.11 | +440.54% | 5 | Dec 5, 2024 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $32 → $40 | $17.84 | +124.28% | 2 | Nov 15, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Outperform | $50 → $65 | $14.29 | +354.86% | 2 | Nov 13, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $92 → $55 | $17.49 | +214.47% | 10 | Nov 7, 2024 | |
| MRSN Mersana Therapeutics | Maintains: Neutral | $4 → $3 | $0.39 | +672.00% | 4 | Aug 14, 2024 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $18 → $17 | $7.85 | +116.70% | 4 | Aug 8, 2024 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $27 → $25 | $5.19 | +381.70% | 1 | Mar 12, 2024 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $72.70 | +44.43% | 1 | Feb 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $6.33 | +3,217.54% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $3.19 | +965.83% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $1.37 | +16,688.32% | 1 | Nov 2, 2021 |
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $17.89
Upside: +129.18%
Agenus
Mar 12, 2025
Maintains: Neutral
Price Target: $6 → $3
Current: $2.85
Upside: +5.26%
Coherus BioSciences
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $1.11
Upside: +440.54%
Enliven Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $32 → $40
Current: $17.84
Upside: +124.28%
Spyre Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $14.29
Upside: +354.86%
Apellis Pharmaceuticals
Nov 7, 2024
Maintains: Outperform
Price Target: $92 → $55
Current: $17.49
Upside: +214.47%
Mersana Therapeutics
Aug 14, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $0.39
Upside: +672.00%
Ocular Therapeutix
Aug 8, 2024
Maintains: Outperform
Price Target: $18 → $17
Current: $7.85
Upside: +116.70%
ORIC Pharmaceuticals
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $5.19
Upside: +381.70%
Nuvalent
Feb 23, 2024
Initiates: Outperform
Price Target: $105
Current: $72.70
Upside: +44.43%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $6.33
Upside: +3,217.54%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $3.19
Upside: +965.83%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $1.37
Upside: +16,688.32%